Sun Pharma gets U.S. FDA nod for Prevacid generic drug

MUMBAI Sun Sep 15, 2013 12:18pm IST

A worker stocks shelves at a temporary CVS store in the Rockaway Beach neighborhood of Queens, New York, November 13, 2012. REUTERS/Brendan McDermid/Files

A worker stocks shelves at a temporary CVS store in the Rockaway Beach neighborhood of Queens, New York, November 13, 2012.

Credit: Reuters/Brendan McDermid/Files

Related Topics

Stocks

   

MUMBAI (Reuters) - Sun Pharmaceutical Industries Ltd (SUN.NS) said its unit has received U.S. Food and Drug Administration's (USFDA) final approval for the generic version of Prevacid.

The approval is for Lansoprazole Delayed-Release Capsules USP, 15 and 30 mg, which are therapeutic equivalents of Takeda Pharmaceutical Co. Ltd's capsules, the company said in a release late on Saturday.

The capsules have annual sales of $430 million in the United Sates, it said.

The capsules are used for short-term treatment for healing and symptom relief of active duodenal ulcer, it said.

(Reporting by Subhadip Sircar; Editing by Robert Birsel)

FILED UNDER:

REUTERS EXCLUSIVE

Reuters Showcase

Documents' Leak

Documents' Leak

India widens oil leaks probe to defence ministry  Full Article 

Bharti-China Mobile

Bharti-China Mobile

Bharti Airtel, China Mobile to collaborate on 4G  Full Article 

Food Security

Food Security

India will not cut multi-billion dollar food handout programme - PM  Full Article 

Rich List

Rich List

Bill Gates tops Forbes rich list, Michael Jordan joins.  Full Article 

Tough Task

Tough Task

India needs sustained GDP growth of 9-10 percent - Jaitley.  Full Article 

Budget 2015

Budget 2015

Budget announcements and reactions from the industry  Full Coverage 

New Credit Cards

New Credit Cards

Insight: Costly shift to new credit cards won't fix security issues   Full Article 

Environment Watch

Environment Watch

Deforestation could shift monsoons, leaving India high and dry.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage